GSK864

Item no.	HY-19540-25mg
Manufacturer	MedChem Express
CASRN	1816331-66-4
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Brain Cancer
Type	Inhibitors
Specific against	other
Purity	99.91
Citations	[1]Okoye-Okafor UC, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol. 2015 Nov;11(11):878-86.
Smiles	FC(C=C1)=CC=C1CN2N=C(C(NC3=CC(C)=C(OC)C(C)=C3)=O)C4=C2[C@](C(N)=O)(C)CN(C(C5=CC=CN5)=O)C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1816331-66-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Isocitrate Dehydrogenase (IDH)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	558.60
Product Description	GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	IDH1
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19540-25mg-safety-datasheet.pdf